Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tiia J. Honkanen"'
Autor:
Peeter Karihtala, Juha P. Väyrynen, Tiia J. Honkanen, Milla E. K. Luukkainen, Antti Tikkanen, Markus J. Mäkinen, Jussi Koivunen
Publikováno v:
Breast Cancer Research and Treatment
Purpose Recent works have characterized that metastatic site can affect the tumour immune profiles and efficiency of cancer immunotherapies. The prognosis of HER2-positive breast cancer is associated with the characteristics of the tumour immune micr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251342d00635c8b4901af7f854f16308
http://hdl.handle.net/10138/353347
http://hdl.handle.net/10138/353347
Autor:
Antti Tikkanen, Tiia J. Honkanen, Juha P. Väyrynen, Peeter Karihtala, Jussi Koivunen, Markus J. Mäkinen
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Disease outcomes of HER2+ breast cancers have dramatically improved after targeted therapies, such as trastuzumab became available. The main mechanism of action of trastuzumab depends on immunoactivation, while immunosuppressive tumour phenotype has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51c70520f48aa7806aaa9fdc8f564718
http://europepmc.org/articles/PMC6662906
http://europepmc.org/articles/PMC6662906
Autor:
Juha P. Väyrynen, Satu Tiainen, Tiina Moilanen, Peeter Karihtala, Tiia J. Honkanen, Jussi Koivunen, Päivi Auvinen, Markus J. Mäkinen
Publikováno v:
Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
Scientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
Disease outcomes of HER2+ breast cancers have dramatically changed after targeted therapies, such as trastuzumab, came to clinical practice but predictive factors for trastuzumab sensitivity and resistance are frequently unknown. Current work include
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e6172426cdf8e39d07d83a085c4a74e
https://pubmed.ncbi.nlm.nih.gov/29269742
https://pubmed.ncbi.nlm.nih.gov/29269742
Publikováno v:
International journal of oncology. 51(2)
We have previously shown that cancer stem-like cells (CSLCs) can mediate therapy resistance in ALK translocated lung cancers. HER2 has been linked to CSLCs in breast cancers and, therefore, we wanted to assess whether HER2 has a role in CSLCs in ALK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6faa1973078360b652438713f0ed3162
https://pubmed.ncbi.nlm.nih.gov/28656214
https://pubmed.ncbi.nlm.nih.gov/28656214
Autor:
Juha P. Väyrynen, Markus J. Mäkinen, Peeter Karihtala, Tiina Moilanen, Jussi Koivunen, Tiia J. Honkanen
Publikováno v:
Cancer Research. 77:1791-1791
Background: Disease outcomes of HER2+ breast cancers have dramatically changed after targeted therapies, such as trastuzumab, came to clinical practice but predictive factors for trastuzumab sensitivity and resistance are frequently unknown. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e7027920f92fe8b04145aeeaf957f56
https://doi.org/10.1158/1538-7445.am2017-1791
https://doi.org/10.1158/1538-7445.am2017-1791